Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) will release fourth quarter and full year 2025 financial results after market close on March 12, 2026 and will host a conference call and webcast at 4:30 p.m. ET.
Replay will be available in the Investors section at capricor.com. Capricor highlighted lead candidate Deramiocel in late-stage development for Duchenne muscular dystrophy and its StealthX exosome platform. The company has an exclusive U.S. and Japan commercialization agreement with Nippon Shinyaku, subject to regulatory approval.
Positive
- None.
Negative
- None.
News Market Reaction – CAPR
In the Mar 9 session, CAPR gained 9.78%, reflecting a notable positive market reaction. Argus tracked a peak move of +16.2% during that session. Our momentum scanner triggered 27 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 10 | Q3 2025 earnings | Positive | +11.5% | Reported Q3 2025 results, HOPE-3 timing, and regulatory/BLA update. |
| Aug 11 | Q2 2025 earnings | Positive | +2.9% | Q2 2025 results, cash runway into Q4 2026, HOPE-3 and StealthX updates. |
| May 13 | Q1 2025 earnings | Positive | +5.1% | Q1 2025 results, strong cash position, BLA priority review status. |
| Mar 19 | FY 2024 earnings | Positive | +17.5% | Q4/FY 2024 results, BLA acceptance with priority review, HOPE-2 data. |
| Nov 13 | Q3 2024 earnings | Positive | +9.3% | Q3 2024 results, rolling BLA, major Nippon Shinyaku deal and financing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and corporate update events have historically driven positive one-day moves, with all recent earnings-tag releases followed by gains.
Over the past year, CAPR’s earnings and corporate updates have coincided with meaningful upside moves, including reactions of 17.51% on Mar 19, 2025 and 11.51% on Nov 10, 2025. These events highlighted strong cash positions, extended cash runway into at least 2027, and steady progress on the Deramiocel BLA and clinical programs. Today’s announcement of upcoming Q4 and full-year 2025 results and a corporate update on Mar 12, 2026 fits this pattern of using earnings calls as key update milestones.
Key Terms
allogeneic medical
exosome-based therapeutics medical
duchenne muscular dystrophy medical
immunomodulatory medical
anti-fibrotic medical
oligonucleotides medical
annual report on form 10-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET –
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.
| Title: | Capricor Therapeutics Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Thursday, March 12, 2026 |
| Time: | 4:30 p.m. ET |
| Call Details: | Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 70035 Participants may dial in using the numbers above and ask to be joined to the call or click the Call me™ link for instant telephone access to the event. |
| Webcast: | Webcast – Click Here |
A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on November 10, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
